Database application model and its service for drug discovery in Model-driven architecture by unknown
Etani Journal of Big Data  (2015) 2:16 
DOI 10.1186/s40537-015-0024-1
RESEARCH Open Access
Database application model and its service




Graduate School of Medicine, Kyoto
University/CREST, Japan Science




Big data application has many data resources and data. In the first stage of software
engineering, a service overview or a system overview cannot be seen. In this paper, we
propose that two processes of “Big data analytics” and “Implementation of data
modeling” should be collaborated with Model-driven architecture (MDA). Data
modeling with those two process in MDA should be repeated fast in order to verify the
data model and to find a new data resource for a service. Our first research goal of big
data application is to predict side effect of drug which is one of screening methods in
drug discovery. This prediction model is constructed with data mining methods at the
intersection of statistics, machine learning and database system. Moreover, a new
service for drug discovery by new uses for old drugs can be found in data modeling
and developed. We demonstrate that the prediction model and the data model for
drug discovery are implemented as a prototype system to verify those models and
their practicality.
Keywords: PLS regression analysis, Discriminant analysis, Support vector machine,
Prediction model, Drug side effect, Drug discovery, Model-driven architecture (MDA)
Introduction
The key properties of big data are characterized as volume, velocity, variety, veracity, and
value [1]. The value (business value) is crucial to offer services for business. To enhance
the value, the veracity, which is about data understandability, is useful for people’s deci-
sion making. Here, the “veracity” of big data properties is an important issue to develop
an application for drug discovery because all of the clinical data is not offered and the
data in drug discovery is sparse. Moreover, in the first stage of software engineering, a ser-
vice overview or a system overview cannot be seen because big data application has many
data resources and data. Therefore, we propose that two processes of “Big data analytics”
and “Implementation of data modeling” should be collaborated with Model-driven archi-
tecture (MDA) [2] in order to repeat data modeling fast and find a new service shown in
Fig. 1. MDA by the Object Management Group (OMG) is a software design approach for
the development of software systems. This architecture has three layers for abstraction
of data modeling because software solutions can be automatically derived from mod-
els by “technology independence”. “Domain model” is modeling the actual existence of a
domain. It is called “Computation Independent Model (CIM)”. “Logical system model” is
modeling a service with domainmodel, in which the components of a system interact with
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Fig. 1 Illustration of the proposed software development process in MDA for big data application. Domain
model, logical system model, and implementation model are three layers for abstraction of data modeling in
MDA. Big data analytics to discover new services and implementation to evaluate an application model
should be collaborated with MDA
each other. It is called “Platform Independent Model (PIM)” “Implementation model” is
modeling a specified system which logical system model can work with a specified tech-
nology and platform, which examples are Linux, Web application and SQL database. It is
called “Platform SpecificModel (PSM)”. Those 5 processes are encapsulated and operated
in parallel.
In this paper, we develop database application model and its service for side effect pre-
diction of drug, which is our first research goal of big data application, and for drug
discovery, which finds new uses for old drugs, introducing the proposed software devel-
opment process in MDA into our research process. Drug side effect prediction is one
of screening methods in drug discovery. The drug candidates can be ranked by this
prediction.
The following sections of the paper are organized as follows: the “Background and lit-
erature review” section will describe background of drug discovery and related works of
side effect prediction and gene-drug discovery. The “Research design and methodology”
section will outline the approach taken by the proposed research of side effect prediction
and drug discovery. The performance of the proposed system will be demonstrated in
the “Results and discussion” section. Finally, the “Conclusions” section will describe a
direction for future.
Background and literature review
In recent years, a research on drug discovery to find the new medical indication from the
old drugs and to redevelop them as a treatment for another disease has attracted attention
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as drug re-positioning in order to minimize cost and a development period for efficiency
[3]. One reason is complex biological processes of most human diseases which the ’one-
drug-one-gene’ approach is not effective to treat [4]. In addition, the official report on the
side effects of prescription drugs that have increased dramatically over the past decade.
In 2011, U.S. Food and Drug Administration (FDA) has received about 500,000 reports of
health hazards and the death related to medical products per year [5]. In considering the
safety of the drug, the prediction of side effect in drug discovery is an important issue for
drug screening. Then, the personalized medicine is expected to develop new drugs and
treatments, and to avoid side effect using Single Nucleotide Polymorphism (SNP) which
will contribute to identifying genes related to the diseases [6]. More than one SNP are in
a gene. Here, previous works on potential side effect prediction of drug candidates and
drug discovery with SNPs using Big Data are reviewed.
The research work to predict the side effects of drugs is done by the relationship
between chemical and target protein. Yamanishi et al. [7] proposed a kernel regression
model as computational model. This method predicted a potential side effect profiles
based on the chemical structures and the information on the target protein. This method
ranked first one of the side effects of 41.7 % (275 drugs) in 658 drugs, and ranked a cor-
rect side effect among the top five scoring for 70.0 % (461 drugs) in 658 drugs. Kuhn
et al. [8] focused on similarities in the side effects of drugs. The clinical data on chemical
and protein were collected. And by combining drug-target protein and drug-side effect
relations, overrepresented target protein-side effect pars are identified. 732 of 1428 side
effects were predicted to be mainly caused by individual proteins. 137 of 732 side effects
were proved by pharmacological or phenotypic existing data. From the results of these
studies, classification and regression characteristics of the side effect are found. However,
these studies will fall into a lack of an overall service-based solution because all data for the
side effect prediction are not always prepared. Although the above-mentioned 2 studies
focused on potential side effect, we focus not only on side effect, but also on its incidence.
Therefore, we propose the comprehensive prediction model of drug side effect and its
incidence using the data mining approach at the intersection of statics, machine learn-
ing and database system considering classification and regression characteristics of the
side effect. And the gene information of target protein and the chemical (drug) - protein
interaction are considered in this paper.
As for gene-drug discovery, Riken developed a method of gene-drug discovery for
rheumatoid arthritis [9]. Genome-wide association study discovered 101 disease genes
of rheumatoid arthritis from SNPs. A new method proved that 101 disease genes were
connected with target proteins of the existing rheumatoid arthritis drugs through protein-
protein interaction network [10]. Moreover, it indicated that the existing drugs for other
diseases were connected to disease genes of rheumatoid arthritis, and that those existing
drugs were possible drug candidates for new uses of rheumatoid arthritis. So, we consid-
ered this results in the clue of drug discovery, and propose database application model to
discover the new drug candidates by new uses of the old drugs.
Research design andmethodology
Data resources
Data from the different databases are publicly available, and collected useful for data
analytics as follows:
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• KEGG: a database resource of biological system [11]. Human diseases, disease genes,
drugs and ATC code [12] are extracted.
• JSNP: a repository of Japanese SNP data [13–15]. Diseases, associated SNPs, and
disease genes are extracted.
• STITCH 4.0: a database of protein-chemical interactions [16]. Confidence score of
chemical (drug) - protein interaction is extracted.
• SIDER 2: a side effect resource to capture phenotypic effects of drugs [17, 18].
Chemical (drug), ATC code, drug side effect, and its incidence are extracted.
• PubChem: a database of chemical molecules [19]. Chemical ID according to drug
number in the KEGG database is extracted.
Data features
Drug
In drug discovery, drug candidates are selected by the interaction with target proteins
including disease genes of human organ or system. So, the properties of drug are char-
acterized as biological, anatomical, genetic, and clinical features. Pinpoint data in each
feature is selected. Confidence score of chemical (drug) - protein interaction as biologi-
cal feature, the first level of ATC code as anatomical feature, Gene ID of disease gene as
genetic feature, and side effect and its incidence as clinical feature are utilized. As for ATC
code, the Anatomical Therapeutic Chemical (ATC) Classification System uses it, which
is controlled by the World Health Organization Collaborating Center for Drug Statistics
Methodology, to classify drugs into five different groups according to the organ or system
on which they act and their therapeutic and chemical characteristics [12, 20]. Here, the
first level, that is the anatomical main group according to the organ or systemwhich drugs
act, is utilized. It consists of one letter. There are 14 anatomical groups as follows: (A) Ali-
mentary tract and metabolism, (B) Blood and blood forming organs, (C) Cardiovascular
system, (D) Dermatologicals, (G) Genito urinary system and sex hormones, (H) Sys-
temic hormonal preparations, excluding sex hormones and insulins, (J) Antiinfectives for
systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculo-skeletal
system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R)
Respiratory system, (S) Sensory organs, and (V) Various.
There are 334 drugs which show their incidences of more than 0.1 % in the SIDER 2
database. The number of the side effect which is extracted from the SIDER 2 database is
2326. The highest scores for these 334 drugs as biological feature are extracted from the
STITCH 4.0 database. 76 drugs among 334 drugs have the disease genes in the KEGG
database. The number of the gene which is extracted from the KEGG database is 335.
Gene
2385 disease genes, in which 801 genes have the drugs, are extracted from the KEGG
database. 11490 SNPs and 6513 genes, whose diseases are also nominated in the KEGG
database, are extracted from the JSNP database.
Disease
717 diseases, in which 174 diseases have the drugs, are extracted from the KEGG
database. 64 diseases, which are also nominated in the KEGG database, are found in JSNP
database.
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Prediction model
Side effect prediction
The first level of ATC code in 334 drugs and Gene ID of the disease gene in 76 drugs can
classify the side effects. As for ATC code, Table 1 shows the number of the side effect
which is classified by the first level of ATC code. For example, “(L) Anti-neoplastic and
immunomodulating agents” of ATC code can find 970 side effects which are including the
typical symptoms of leukemia, lymphopenia and thrombocytopenia. As for the disease
gene, side effects can be derived from the drug which is interacted with the disease gene.
For example, the “HLA-DQA1” gene, which provides instructions for making a protein
that plays a critical role in the immune system, can find 130 side effects extracted from
the drugs of propanolol, simvastatine, dipyridamole and azathioprine which have it as the
disease gene.
Incidence prediction
As for clustering method, discriminant analysis using regression formula is utilized to
classify the data with 2 classes. In Table 2, “SCORE”, “ATC”, and “Gene ID” in pin-
point data are the explanatory variables. The response variable is “Incidence”. All of those
explanatory variables are not always prepared because the data is sparse. So, 7 dataset
patterns of pinpoint data are prepared to be able to predict side effect incidence even if
some of those explanatory variables are missing. A mark on Table 2 indicates the existing
pinpoint data.
Firstly, each dataset is analyzed with regression analysis of a statistical method. Sec-
ondly, discriminant analysis (DA) sets a discriminant criterion from the results by the
regression analysis, and classifies the group by the criterion. Linear discriminant formula
calculates a value which can classify the group. Then, each DA value is divided into the
positive group or the negative group. In the regression analysis, single regression analysis
in case of one explanatory variable is available, and partial least squares (PLS) regression
analysis in case of more than one explanatory variable is available because a problem of
multicollinearity may be occurred and it is difficult to decide the group border when one
explanatory variable has correlation with another explanatory variable. When DA using
multiple regression analysis is executed in a case of Dataset No. 4 shown in Table 2, Fig. 2
shows that it is difficult to decide the group boundary because there is variability around
the threshold which value is “0”. Instead of multiple regression analysis, PLS regression
analysis is introduced. As a result, Fig. 3 shows that it is easy to decide the group boundary
at 34.7 %.
Table 1 The number of side effect classified by the first level of ATC code
ATC The number of side effect ATC The number of side effect
ALL 2326 L 970
A 642 M 652
B 264 N 1704
C 632 P 113
D 379 R 380
G 523 S 914
H 132 V 191
J 702
“ATC” indicates the first level of ATC code. “The number of side effect” shows the results of side effect classification by the first
level of ATC code
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Table 2 Dataset of pinpoint data in Drug properties
Dataset No. SCORE ATC Gene ID Incidence Items
1 ◦ ◦ ◦ 358
2 ◦ ◦ 262
3 ◦ ◦ 214
4 ◦ ◦ ◦ ◦ 469
5 ◦ ◦ ◦ 334
6 ◦ ◦ ◦ 469
7 ◦ ◦ 334
“Dataset No.” indicates 7 dataset patterns with pinpoint data of each drug property. “SCORE” indicates confidence score of
chemical (drug) - protein (disease gene) interaction as biological feature. “ATC” indicates the first level of ATC code as anatomical
feature. “Gene ID” indicates Gene ID of disease gene as gene feature. “Incidence” indicates side effect incidence as clinical feature.
“Items” indicates the number of the data in each dataset
This model is described as follows: An example formula of PLS regression model in
Dataset No. 4 shown in Table 2 can be represented as
y′ = a1 ∗SCORE + a2 ∗ACT + a3 ∗Gene ID + b (1)
where y′ is predicted value, a1 is coefficient of explanation variable SCORE, a2 is coeffi-
cient of explanation variable ATC, a3 is coefficient of explanation variable Gene ID and b
is intercept. A formula of PLS-DA can be represented as
f(x) = y − y′. (2)
y is observed value. Discrimination rule is as follows: If f (x) ≥ 0 Then sgn [f (x)] = 1 and
If f (x) < 0 Then sgn
[
f (x)
] = −1. Finally, each data is analyzed with DA and classified
with 2 classes until one group in one class cannot be classified. As a result, Table 3 shows
the clustering. And it indicates that the clustering is available with almost 100 % correct
rate.
Fig. 2 Discriminant Analysis with 2 classes by Multiple Regression formula in Dataset No. 4. This shows a
result of the first grouping of the data in Dataset No. 4 shown in Table 2 by discriminant analysis with 2
classed using multiple regression formula. The threshold value is “0” to classify DA values with a positive class
or a negative class
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Fig. 3 Discriminant Analysis with 2 classes by PLS regression formula in Dataset No. 4. This shows a result of
the first grouping of the data in Dataset No. 4 shown in Table 2 by discriminant analysis with 2 classed using
PLS regression formula. The threshold value is “0” to classify DA values with a positive class or a negative class.
34.7 % can be a group boundary for clustering
As for prediction method, Support Vector Machine (SVM) is supervised learning
models with associated learning algorithms that analyze data and recognize patterns. A
training algorithm of SVM learns the rules and creates the learning model. SVM takes
a set of input data and predicts with the learning model. LibSVM Version 3.18 [21] for
a machine learning library is available. The example model in Dataset No. 4 shown in
Table 2 is described as follows: When there are n samples of Dataset No. 4, input space
can be represented as
X = (SCORE1,ATC1,GeneID1), · · ·, (SCOREn,ATCn,GeneIDn). (3)
Table 3 Evaluation of clustering
Dataset No. Clustering Correct rate (%) Dataset No. Clustering Correct rate (%)
1 41 –100 % 99 5 34.7 –100 % 100
2 55 –100 % 96 27.4 –100 % 100
29 –100 % 100 12.1 –100 % 100
9 –100 % 100 6 53.2 –100 % 95
3 70.3 –100 % 100 51 –100 % 100
36 –100 % 99 50 –100 % 100
18 –100 % 100 34.7 –100 % 100
4 81.7 –100 % 100 27.4 –100 % 100
63.5 –100 % 100 18 –100 % 100
34.7 –100 % 100 12.1 –100 % 100
27.4 –100 % 100 7 81.7 –100 % 100
12.1 –100 % 100 49 –100 % 100
5 94 –100 % 100 18 –100 % 100
“Dataset No”. indicates 7 dataset patterns of pinpoint data shown in Table 2. “Clustering” indicates the group divided by DA.
“Correct rate” indicates to what extent each example can be classified with each correct clustering
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Output domain can be represented as Y = {1,−1}. A formula of class classification can
be represented as f (x) =< w · x > +b where w is weight vector, and b is bias. Classifica-
tion rule is as follows: If f (x) ≥ 0 Then sgn[ f (x)]= 1 (positive class) and If f (x) < 0 Then
sgn[ f (x)]= −1 (negative class). Table 4 shows evaluation of each learning model for pre-
diction by SVM. It indicates that the prediction models are available with almost 100 %
correct rate.
As for prediction procedure, firstly, new dataset is classified into one dataset pattern
shown in Table 2. Secondly, in descending order of the clustering, SVMwill response true
or false to predict the lower value of the prediction interval. In a case of Dataset No. 2
shown in Table 2, there are 3 intervals shown in Table 3. When a parameter of SVM is
the lower value of “55” and SVM responses false, the parameter is changed to the next
interval’s lower value of “29”. When SVM responses true in this parameter, it is decided
that side effect incidence will be from 29 % to 100 % in the approximated interval. When
SVM responses false with the last parameter of “9”, it is decided that side effect incidence
will be from 0.1 % to 100 % in the approximated interval.
Data modeling
Datamodeling for side effect prediction is done, and its model is implemented to verify its
service. After that, the data concerning gene is collected from the KEGG database and the
JSNP database. In addition to side effect prediction, new services for drug discovery are
found in data modeling. Here, the result of modeling database application in each model
is described.
Domainmodel
Figure 4 shows a static view of the objects in an application for side effect prediction and
drug discovery. There are 6 domain objects and their relations. 6 domain objects consists
Table 4 Evaluation of learning model
Dataset No. Clustering Correct rate (%) Dataset No. Clustering Correct rate (%)
1 41 –100 % 100 5 34.7 –100 % 100
0.1 –100 % 100 27.4 –100 % 99.5
2 55 –100 % 23 12.1 –100 % 99.6
29 –100 % 95 0.1 –100 % 100
9 –100 % 40 6 53.2 –100 % 100
0.1 –100 % 100 51 –100 % 100
3 70.3 –100 % 100 50 –100 % 100
36 –100 % 90 34.7 –100 % 100
18 –100 % 20 27.4 –100 % 98
0.1 –100 % 86 18 –100 % 98
4 81.7 –100 % 100 12.1 –100 % 99
63.5 –100 % 100 0.1 –100 % 100
34.7 –100 % 100 7 81.7 –100 % 100
27.4 –100 % 100 49 –100 % 100
12.1 –100 % 100 18 –100 % 99
0.1 –100 % 100 0.1 –100 % 100
5 94 –100 % 100
“Dataset No”. indicates 7 dataset patterns of pinpoint data shown in Table 2. “Clustering” indicates the approximated interval of
prediction in side effect incidence of drug. “Correct rate” indicates to what extent each example of learning model can meet each
correct interval in the prediction
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Fig. 4 Domain model. There are 6 domain objects. There are 3 association links among a Drug object, a Gene
object, a Disease object and a SideEffect object. There are 2 aggregation links between a Drug object and an
ATC object, and between a Gene object and a SNP object. The notation 0..* in the diagram means “zero to
many”. And the notation 1..* in the diagram means “one to many”
of a Drug object, an ATC object, a Gene object, a SNP object, a Disease object and a
SideEffect object.
Association indicates any logical connection or relationship between objects. There are
3 association links among a Drug object, a Gene object, a Disease object and a SideEffect
object. One disease contains zero to many drugs. One drug contains zero to many side
effects. And one drug contains one to many genes.
Aggregation indicates the formation of a particular object as a result of one object
built as a collection. In aggregation, the contained objects are not strongly dependent
on the life cycle of the container. There are 2 aggregation links between a Drug object
and an ATC object, and between a Gene object and a SNP object. A Drug object is
made up of none or more ATC codes. And a Gene object is made up of one or more
SNPs.
Logical systemmodel
Figure 5 shows a static view of the objects and classes that make up the design and analysis
space. There are 7 domain objects. A DrugCandidate object is added to 6 domain objects
shown in Fig. 4. They are persistent objects and saved in a database. A Incidence object is
temporary object which is not saved anywhere.
For the class model, 4 new classes for services are modeled. An IncidenceCatalog
class contains one incidence, and uses “Learning Model Files” from Dataset No. 1
to Dataset No. 7 shown in Table 2. A SideEffectCatalog class contains one to many
side effects. Those 2 classes are for drug side effect. A DiseaseClassificationCatalog
class contains one to many diseases. A DrugCandidateCatalog class contains one to
many drug candidates, and uses “Drug Candidate Files” which consists of Gene ID,
Chemical ID, and Score. Those 2 classes are for drug discovery by new uses for old
drugs.
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Fig. 5 Logical systemmodel. There are 7 domain objects as persistent objects, which diagrams are green, and
one object as temporal object, which diagram is white. For the class model, 4 new classes for services, which
diagrams are blue, are modeled. And each attributes and each behavior are described in each object and class
In class design, the class model expresses both the persistent state and the behavior of
the system. The state (attributes) are encapsulated in a class, and manipulated to offer
services by a class (behaviors). Each attributes and each behaviors are modeled in each
class and object.
Implementationmodel
Figure 6 describes an implementation-specific solution to satisfy what is specified by the
logical system model. Figure 6 shows database application model with web application.
There are 6 tables. They realize 6 objects by object-relational mapping. ADisease object is
realized by “Disease” table. A Drug object is realized by “Disease” table and “Drug” table.
A Gene object is realized by “Disease” table and “Gene” table. A SNP object is realized by
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Fig. 6 Implementation model. There are 6 tables of database, which diagrams are red. They realize 6 objects
by object-relational mapping
“Jsnp” table. A SideEffect object is realized by “SideEffect” table. A DrugCandidate object
is realized by “Interaction” table.
Implementation
System overview
Figure 7 shows system overview to realize the implementationmodel shown in Fig. 6. This
system consists of a database with 6 tables and two file groups. A database is accessed
with SqlTool and Web application. Both file groups are accessed with Web application.
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Fig. 7 System overview. Implementation model shown in Fig. 6 is realized in the database application. This
system consists of a database with 6 tables and two file groups. There are 3 ways of “SqlTool”, “Web
Application” and “Linux Command” to access this system
One file group of “Drug Candidate” is also accessed with Linux command. It is freely
accessed to search for new interaction pairs by Gene ID and chemicalID. Using this
database, the clustering is created by statistical regression analysis and discriminant anal-
ysis, and SVM creates the learning model with the clustering. When the data is input
in incidence prediction, its incidence is calculated with those learning model files using
SVM.
Software overview
Table 5 shows software development environment. As forWeb application, open source is
adopted. In order to develop a prototype system to evaluate themodels, the domain object
of Book Management System (bcat) [22], which is free-ware, is utilized. As a prototype
system, Tomcat server can be connected to web browser by port 8080 in the development
environment of Java2SE.
Figure 8 shows software overview for Web application. Web server and Servlet/Jsp
container are working by Tomcat. Struts framework can work on Servlet/Jsp container.
Table 5 Software development environment. Open source and free ware are publicly available
Open Source
OS: Linux Fedora 20
IDE: Eclipse 4.3.2 (KEPLER)
Java: 1.7.0_55
Application Framework: Struts 1.3.10
Web container/HTTP/Web server: Tomcat 7.0.53
Database: HSQLDB 2.3.2
Machine learning library: LibSVM 3.18
Free ware
Domain object: Book Management System (bcat)
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Fig. 8 Software overview for Web Application. The Hypertext Transfer Protocol (HTTP) is an application-level
protocol to connect web browser with web application on Tomcat server. ActionForm for model, JspPage for
view, and ActionClass for controller to operate 7 domain objects are consisted in software for web application
The prototype System with Struts framework are integrated by three components of
ActionForm, ActionClass, and JspPage to operate 7 domain objects.
Application
Side effect Prediction There are two services of side effect prediction and incidence pre-
diction for Web application. Figure 9 shows operation screens for side effect prediction.
When the input data is received, side effects are classified by the input data and shows its
result. Figure 10 shows operation screens for incidence prediction. When one dataset of 3
input items is received from input form, its incidence is calculated by LibSVM using class
Runtime. Those 3 input items correspond to the explanatory variables of “SCORE”, “ATC”,
and “Gene ID” shown in Table 2, and Equation 3. After that, the result of calculation is
displayed.
Drug Discovery by new uses for old drugs There are two approaches. The first
approach is to discover drug candidates in new chemicals (drugs)-proteins (disease genes)
interactions. A DrugCandidateCatalog object shown in Fig. 6 offers a service to search
new chemicals (drugs)-proteins (disease genes) interactions by disease gene. Moreover,
when a file group of “Drug Candidate” are directly operated by Linux commands, inter-
active other genes can be searched by the drugs which are combined with disease genes.
The second approach is to discover drug candidates in the disease group related by dis-
ease genes and SNPs. Using SqlTool, diseases can be grouped with the common SNP and
gene. Diseases which has no drugs can find the drug candidates when other diseases in
the same group have the drugs.
Results and discussion
Side effect prediction
The accuracy in the proposed Web application is evaluated using 9 drugs, which are not
nominated in the SIDER 2 database and extracted from the side effect list of “The Internet
Drug Index” [23].
As for side effect prediction, 93 % (197 side effects) in 211 side effects can be predicted
when ATC code is classified. The reasons why 7 % (14 side effects) in 211 side effects
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Fig. 9 Operation screen for side effect prediction. The left screen shows an input form for side effect
prediction. The right screen displays the result which side effects are classified by 2 input items
cannot be predicted are as follows: 6 side effects are not nominated in this database; 7
side effects are not be classified although they are nominated in this database.
As for incidence prediction, there are 335 items to be predicted in side effect incidence.
They are predicted according to each dataset shown in Table 2. Table 6 shows that 99.7 %
of 335 items in Dataset No. 1 gets the approximated intervals of incidence, and that 0.3 %
of them gets the higher intervals in the prediction. It will conclude that the gene informa-
tion is useful for incidence prediction, and that the score as biological feature to extract
regression characteristics of side effect contributes to predicting side effect incidence.
Thus, the proposed model can predict the approximation of side effect and its
incidence. This is an important result of the prediction model. When clinical data of
drugs are not prepared for drug screening, pinpoint data which shows drug properties are
available for predicting side effect by the proposed model.
Drug discovery by new uses for old drugs
In the first approach of discovering drug candidates in new chemicals (drugs)-proteins
(disease genes) interactions, the number of new uses for old drugs is evaluated in the
proposed database application. The procedure of extracting new drug candidates from
the database with SqlTool is as follows: first, to extract Gene ID and chemical ID pairs
from Gene, Drug, and Disease tables; second, to extract Gene ID and chemical ID
pairs in the drug candidate files searched by the extracted chemical ID; third, to extract
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Fig. 10 Operation screen for incidence prediction. The left shows an input form for side effect incidence. The
right screen displays the result which side effect incidence is calculated with 3 input items by LibSVM
new combinations by excluding Gene IDs nominated in the first result from Gene IDs
nominated in the second result.
As a result, 32 new drug candidates of old drugs can be found. Among them, three
drug candidates for three genes which has no drugs in the KEGG database and one drug
candidate for one gene which has some drugs in the KEGG database are discovered as a
therapeutic agent. The former three new drug candidates are “hydroxyurea” for NBN gene
of primary immunodeficiency or congenital disorder of DNA repair systems, “probucol”
for COG1 gene of inherited metabolic disease, and “pyridoxine” for SLC25A38 gene of
Table 6 Performance of incidence prediction
Dataset No. Approximated interval Higher interval
1 99.7 % 0.3 %
2 97 % 3 %
3 11 % 89 %
4 98 % 2 %
5 76 % 24 %
6 71 % 29 %
7 44 % 56 %
“Dataset No”. indicates 7 dataset patterns of pinpoint data shown in Table 2. “Approximated interval” indicates correct rate which
a drug side effect incidence can be predicted within a correct clustering. “Higher interval” indicates that the predicted interval is
higher than a correct interval of a drug side effect incidence
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hematologic disease. The latter one drug is “IMIQUIMOD” for TLR9 gene of immune
system disease.
In the second approach of discovering drug candidates in the disease group related by
disease genes and SNPs, the number of disease which can discover the new drug candidate
is evaluated. The procedure of extracting diseases which can discover new drug candidate
is as follows: first, to extract diseases which have the common SNPs or disease gene from
two tables of “Gene” and “Jsnp”; second, when some diseases have the common SNP or
disease gene, those diseases are related with each other and grouped with the grouping
tool developed in Java.
As a result, 717 diseases in which 174 diseases have the drugs are classified into 187
groups. 93 groups have no drugs. 94 groups have some diseases which have some drugs.
Then, 328 disease can discover the new drug candidates by the disease group.
Conclusion
This paper describes database application model and its service for drug discovery
introducing our proposed software development process in MDA into our research pro-
cess. The issue of veracity can be solved when pinpoint data are selected from drug
properties in big data analytics with domain model. The datasets of pinpoint data are
designed to predict side effect and its incidence even if some of pinpoint data are missing.
The proposed prediction model of side effect and its incidence can attain almost 100 %
accuracy in its performance. In addition to our first research goal of side effect predic-
tion in drug discovery, we can discover 2 new services for drug discovery by new uses for
old drugs in logical system model with big data analytics. The veracity can be strength-
ened based on the number of disease gene directly interacted to chemicals (drugs) and
the number of the disease gene and SNPs contributing to human disease. So far, it can be
concluded that the reputation of data modeling with data analytics and implementation
can strengthen the “veracity” of big data.
Our approach of software development process in MDA will be useful for devel-
oping a big data application and a new service by “veracity” and “value” of big data
because MDA provides an approach for deriving value from models and architecture.
Our proposal will contribute to the personalized drug discovery with drug screening
of side effect prediction in the personalized medicine although our proposed system is
comprehensive.
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